Serum concentrations of 25-hydroxyvitamin D and immunoglobulins in an older Swiss cohort: results of the Senior Labor Study. by Sakem, Benjamin et al.
Sakem et al. BMC Medicine 2013, 11:176
http://www.biomedcentral.com/1741-7015/11/176
s
o
u
r
c
e
:
 
ht
tp
:/
/b
or
is
.u
ni
be
.c
h/
54
00
3/
 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7RESEARCH ARTICLE Open AccessSerum concentrations of 25-hydroxyvitamin D
and immunoglobulins in an older Swiss cohort:
results of the Senior Labor Study
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and Lorenz Risch1,6,7*Abstract
Background: Vitamin D and the components of humoral immunity play important roles in human health. Older
people have lower 25-hydroxyvitamin D (25(OH)D) serum levels than younger adults. We aimed to determine the
levels of 25(OH)D serum concentrations in healthy senior citizens and to study their relationship to the levels of
components of humoral immunity.
Methods: A total of 1,470 healthy Swiss men and women, 60 years or older, were recruited for this study. A total of
179 subjects dropped out of the study because of elevated serum concentrations of C-reactive protein. Fasting
blood sera were analyzed for 25(OH)D with the high-performance liquid chromatography (HPLC) and for
parathyroid hormone (PTH), immunoglobulins and complement C4 and C3 concentrations with immunoassays. The
percentage of participants in each of the four 25(OH)D deficiency groups - severely deficient (<10 ng/ml), deficient
(10 to 20), insufficient (21 to 29 ng/ml) and normal (>=30 ng/ml) - were statistically compared. The relationship of
the major components of the humoral system and age with 25(OH)D levels was also assessed.
Results: About 66% of the subjects had insufficient levels of 25(OH)D. Normal levels of 25(OH)D were found in
26.1% of the subjects of which 21% were males and 30.5% were females (total study population). Severely deficient
levels of 25(OH)D were found in 7.98% of the total study population. Low levels of 25(OH)D were positively
associated with IgG2 (P = 0.01) and with C4 (P = 0.02), yet were inversely related to levels of IgG1 and IgA (P < 0.05)
and C3 (P = 0.01). Serum levels of total IgA, IgG, IgG2 and IgG4 peaked together with 25(OH)D during late summer.
Conclusions: Approximately two-thirds of the healthy, older Swiss population presented with Vitamin D
insufficiency. The incremental shift in IgA and C3 levels might not necessarily reflect a deranged humoral immune
defense; however, given the high prevalence of vitamin D deficiency, the importance of this condition in humoral
immunity will be worth looking at more closely. This study supports the role of vitamin D in the competent
immune system.
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The biological role of fat-soluble vitamin D has been shown
in recent studies to extend far beyond its role in calcium
homeostasis and bone health [1-4]. Currently, the structure
of vitamin D receptors (VDRs) and their functions are well
understood. Once the receptors bind to their ligand, VDRs
dimerize with an isoform of the retinoid X receptor (RXR).
Many body tissues express VDR; furthermore, VDR-RXRs
are found on a variety of cells, including monocytes/
macrophages [3], kidney cells [5], cardiomyocytes [6],
skin cells [7] and liver cells [8]. At each corresponding
organ site, the vitamin D/VDR system is associated
with functional organ performance.
Experimental, epidemiological and clinical studies have
shown inverse associations of low vitamin D status with
longevity and with retarding immunosenescence [9]. 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) blocks the induction
of T-helper-1 (TH1)-cell cytokines (for example, IFNγ) and
promotes TH2-cell responses. This activity partly explains
the decreased B-cell proliferation, plasma-cell differenti-
ation and IgG secretion [6,9,10], which is an activity that
conserves efficient immune defense (in particular anti-viral)
[3]. The actions of 1,25(OH)2D3 on B cell function
have been researched for many years [10] and this area
has recently received interest regarding the mechanisms
of action [6,11-14]; for example, a recent study described
an inverse relation of serum total IgG levels with serum
25-hydroxyvitamin D (25(OH)D) [15]. Although some re-
sults remain to be confirmed, low serum 25(OH)D levels
have been linked to all-cause cardiovascular, cancer and
infection-related mortality and also to stroke. Furthermore,
autoimmunity and some infectious agents may also cause
disease because of insufficient 25(OH)D [11].
Throughout the life span, a significant proportion
of humans have insufficient (<30 ng/ml) or deficient
(<20 ng/ml) serum 25(OH)D levels. 25(OH)D severe defi-
ciency may be defined as serum concentrations <10 ng/ml
[16,17], deficiency as values <20 and insufficiency as 21
to 29 ng/ml, whereby values >30 ng/ml (75 nmol/L)
shall reflect a sufficient concentration [2,18,19]. Regular
exposures to sunlight foster the required hydroxylations to
produce the bioactive compound. The first –OH attach-
ment results in 25-hydroxyvitamin D and the second in
1,25-dihydroxyvitamin D (1,25(OH)2D). Humans acquire
much of their vitamin D through a photosynthetic reaction
in the skin with a small amount via digestive intake [20].
Those at risk for vitamin D deficiency are those with little
sun exposure and/or poor dietary intake. Older people are
especially at risk because aging lowers the amount of 7-
dehydrocholesterol in the skin, reducing the capacity for
vitamin D production. People with dark skin have a signifi-
cantly lower mean serum level of 25(OH)D than those with
light skin across the life-span, but dark skin people have a
lower level of vitamin D-binding protein and consequentlymore bioactive Vitamin D [21]. The acquisition of Vitamin
D may be hampered by increased melanin production, as is
the case with dark skin or with increased age [22].
The European population is known for transient re-
ductions of 10 to 20% of individual 25(OH)D serum
levels measured during the winter months compared
to the summer months, an observation that is particularly
prominent in the older people [23].
The present study was initiated (i) to study the prevalence
of insufficiency and deficiency levels in healthy older people
and (ii) to assess the impact of these deficiencies on
immunoglobulin and complement components C4 and
C3 production.
Methods
Study population
Consecutive subjectively healthy, older volunteers aged 60
years and older were recruited between February 2009 and
July 2010 as part of the Senior Labor Study, which is an
ongoing investigation in the canton of Berne (Switzerland)
initially aimed at creating appropriate reference intervals
(RIs) for several analytes in older persons (http://www.
seniorlabor.ch). The study participants were contacted
through newspaper advertisements and different clubs and
associations that had a high probability of having healthy,
older members (for example, alpine clubs, sports clubs) and
through the personal contacts of collaborators of the study
organization.
A personal history of each subject was taken, anthropo-
metric measurements were performed, and fasting venous
blood was drawn into S-Monovette tubes (Sarstedt, Sevelen,
Switzerland). Of the 1,470 participants, 179 with a high total
leukocyte count (>11.5 G/L) and/or high C-reactive protein
levels (>5 mg/L) were excluded from further analysis since
such laboratory cutoffs are strong indicators of the presence
of systemic inflammation, mostly for upper respiratory tract
infections. Of the remaining 1,291 subjects, 558 were be-
tween 60 and 69 years old, 498 between 70 and 79 years old
and 235 were 80 years old or older (Table 1).
This study was conducted in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki, and
informed consent was obtained from all participants.
Ethical approval for the present study was obtained from
the Berner Kantonal Ethics committee (KEK-Berne-Study
Nr 166/08), Bern, Switzerland.
Laboratory testing
All assays were done at our institution. For 25(OH)D
concentration measurements, we used the LaChrom Elite
apparatus provided by Hitachi (Hitachi Medical Systems
Europe, Zug, Switzerland). 25(OH)D2 and 25(OH)D3
(derived from cholecalciferol) were distinguishable using
this method; for this study, only the latter, more stable
animal-origin 25(OH)D3 levels are reported. The US
Table 1 Percentage of healthy older subjects in the different groups of vitamin D deficiency according to gender
25(OH)D (ng/ml)
Men (600) Women (691) Total (1,291)
Age groups <10 10 to 20 21 to 29 ≥30 <10 10 to 20 21 to 29 ≥30 <10 10 to 20 21 to 29 ≥30
60 to 69 (558) 4.4 29.3 39.9 26.4 3.5 26.7 32.3 37.5 3.9 28.5 36.0 32.1
70 to 79 (498) 10.1 38.3 29.1 22.5 8.5 26.6 30.3 34.7 9.2 31.9 29.7 29.1
≥80 (235) 13.0 36.0 28.0 23.0 16.3 38.5 20.0 25.2 14.9 37.5 23.4 24.6
Total (1,291) 8.0 33.8 33.8 24.3 8.0 28.9 29.1 34.0 8.0 31.2 31.3 29.5
Numbers are percentages of participants classified according to 25(OH)D level group: <10 ng/ml (severe deficiency), 10 to 20 ng/ml (deficiency), 21 to 29
(insufficiency) ng/ml and ≥30 ng/ml (normal).
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calibration standard reference material (http://www.nist.
gov) was consistently followed with each test batch,
and only the values complying with the requirements
were released; the inter- and intra-assay variations were
<5%. The baseline total 25(OH)D levels were catego-
rized as normal, insufficient, deficient and severely de-
ficient using levels adapted from the definitions proposed
earlier [17,24]. The IMMULITE 2000 assay (Siemens
Healthcare Deutschland, Erlangen, Bavaria, Germany) was
used for quantification of serum 1 to 84 parathyroid hor-
mone (PTH); this is a solid-phase two-site chemilumin-
escent immunoassay with a monoclonal mouse capture
antibody and a polyclonal goat signal antibody conjugated
to alkaline phosphatase.
The levels of immunoglobulins, where applicable, were
measured using the BN Prospec® Nephelometry System
(Siemens, Zurich, Switzerland), incorporating stabilized
human serum as the N Protein Standard SL. Subclass-
specific sheep anti-human IgG1 and IgG2 were used in10.0
20.0
30.0
40.0
50.0
60.0
60 70 80 90 100
Age (yrs)
A
0.0
Figure 1 25(OH)D levels in healthy older Swiss citizens. A: The regressi
(P < 0.01). B: The same data as in A were sorted into three age groups and
of 25(OH)D levels by decrements of median and interquartile ranges in relaconventional nephelometry and anti-human IgG3 and
IgG4 in this system is loaded on polystyrol particles to
enhance sensitivity for quantitation of the cognate sub-
class. For C3 und C4, we used sodium azide preserved
anti-C3c antibodies <6.4 mg/ml and anti-C4 <5.4 mg/ml.
The company recommends application of the following
reference intervals established with serum and/or plasma
samples from healthy adults: C3/C3c of 0.9 to 1.8 mg/ml
and C4/C4c of 0.1-0.4 mg/ml.Statistical procedures
The serum concentration values of 25(OH)D, immuno-
globulin classes, IgG subclasses and complements were
statistically analyzed using SPSS version 17.0 for Microsoft
Windows (SPSS, Inc., Chicago, IL, USA). All statistical
analyses were based on two-sided hypothesis tests with a
significance level of P <0.05. The Kruskal-Wallis test was
used to test for statistically significant associations of 25
(OH)D and immunoglobulins in more than two groups.B
P<0.001
P=0.009
P=0.001
10.0
20.0
30.0
40.0
0.0
60-69 70-79 ≥ 80
Age (yrs)
on line illustrates reduction of these levels in 1,291 men and women
are here represented in box plots. They further illustrate the decrease
tion to aging.
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tically compare the levels of various immunoglobulins and
complement components by categories of 25(OH)D levels
(normal, insufficient, and deficiency groups). Univariate
linear regression analysis was used to examine the rela-
tionship between 25(OH)D as the dependent variable
and age, immunoglobulin and complement components
as the independent variables.
Results
The entire cohort of 1,291 people studied revealed a
significant correlation between aging and 25(OH)D levels
(Figure 1A). To analyze in detail the effect of aging on 25
(OH)D, participants were divided into three age groups
(60 to 69 years, 70 to 79 years and >80 years) (Figure 1B).
Only 26.1% of the subjects had normal 25(OH)D levels
(>30 ng/ml). These consisted of 21% of the males and 30.5%
of the female participants of the total study population. The
detailed distribution of the subjects into the respective 25
(OH)D deficiency groups is presented in Table 1. SevereTable 2 PTH, immunoglobulins and complement C4 and C3 le
(OH)D in 1,291 healthy older subjects
Analyte
<10 10 to 20 21 t
N = 103 N = 403 N =
PTH 7.87 ± 0.51* 4.78 ± 0.13 4.25
pg/ml
IgA 2.32 ± 0.10 2.12 ± 0.05 2.22
mg/ml
IgE 145.38 ± 50.1 75.45 ± 10.08 85.01
kU/l
IgM 0.88 ± 0.05 0.94 ± 0.04 0.96
mg/ml
IgG 10.63 ± 0.25 10.05 ± 0.11 10.28
mg/ml
IgG1 6.74 ± 0.21 6.16 ± 0.08 6.17
mg/ml
IgG2 3.13 ± 0.15 3.23 ± 0.07 3.45
mg/ml
IgG3 0.38 ± 0.02 0.37 ± 0.01 0.38
mg/ml
IgG4 0.66 ± 0.06 0.60 ± 0.03 0.66
mg/ml
C4 0.22 ± 0.01 0.23 ± 0.00 0.23
mg/ml
C3 1.11 ± 0.02 1.09 ± 0.01 1.7 ±
mg/ml
* Mean ± 1 SD.
+Sd/Nor: between the groups of Severely deficient and Normal serum concentration
Differences between groups were assessed by Kruskal-Wallis test.25(OH)D deficiencies (levels <10 ng/ml) were observed
in 8.0% (M: 8.0%, F: 8.0%) of the subjects. However, it
should be noted that subjects became increasingly 25
(OH)D deficient with increasing age, with a prevalence
of severe deficiency 3.5%, 8.5% and 16.3% in women and
4.4%, 10.1% and 13.0% in men in the progressively older
age groups (Table 1). About 50% of the healthy older
Swiss over 70 years have insufficient 25(OH)D levels.
Serum PTH levels inversely correlated with 25(OH)D)
(P <0.001) (Table 2). 25(OH)D levels were significantly
different according to the month the samples were col-
lected (P <0.001) (Additional file 1).
We also evaluated the relationship between 25(OH)D
levels and major humoral components of innate and
acquired immunity. While levels of IgA inversely correlated
to 25(OH)D, IgM nor of total IgG or IgE differed from
changing 25(OH)D levels (Figure 2 and Table 2).
The P-values were obtained by either using the Kruskal
Wallis analysis across the board for trend or by comparing
the 25(OH)D severely deficient and the normal group.vels compared among four concentration ranges of 25
25(OH)D
o 29 ≥30 P-value
404 N = 381 Trend Sd/Nor+
± 0.10 3.73 ± 0.10 <0.01 <0.01
± 0.05 2.12 ± 0.05 0.12 0.036
± 13.17 70.37 ± 7.89 0.28 >0.05
± 0.03 0.98 ± 0.03 0.09 >0.05
± 0.10 10.28 ± 0.12 0.24 >0.05
± 0.07 6.41 ± 0.11 0.14 0.033
± 0.07 3.24 ± 0.06 0.01 >0.05
± 0.01 0.41 ± 0.03 0.37 >0.05
± 0.03 0.59 ± 0.02 0.12 >0.05
± 0.00 0.23 ± 0.00 0.02 0.01
0.007 1.07 ± 0.01 0.03 0.01
s of 25(OH)D.
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Figure 2 Box and whisker plot of the relationship between immunoglobulin levels and 25(OH)D. A: IgA levels, B: IgE levels, C: IgM levels
and D: IgG levels, compared among the different deficiency groups of 25(OH)D in the healthy, olderSwiss population. P-values are indicated only
when statistically significant.
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among 25(OH)D level groups (Table 2). Further, com-
plement component C4 increased with increasing 25(OH)
D (Figure 3A, B), whereas complement component C3
decreased with increasing 25(OH)D (Figure 3C, D).
Seasonal variation in immunoglobulin levels and com-
plement components revealed differences according to the
month samples were taken (Additional file 2). Significant
differences were observed for total IgG (P = 0.001), IgG2
(P = 0.003), IgG4 (P = 0.04), complement component C4
(P = 0.01), and complement component C3 (P = 0.006).
Total IgG, IgG2 and IgG4 peaked together with 25(OH)D
during August.
Discussion
This is the first time that the 25(OH)D status has been
connected to humoral immunity features in healthy
older subjects not receiving any real-time medical care;
in fact, most studies reporting insufficient/deficient 25(OH)D levels have been performed in the context of
disease, such as patients assigned to primary care [25],
or having a risk for bone fractures [26], prostate cancer
[27], cardiovascular disease [28], and evaluations in re-
sponse to influenza or recombinant hepatitis B vaccine
[29,30]. Some authors have questioned the quality of
such studies, mainly for technical reasons [31]. Our
study is in line with recent epidemiological investigations
demonstrating a high prevalence of mild and severe 25
(OH)D deficiency; in one such study, this deficiency
did not significantly increase with aging [32], whereas
it did in another [33].
Here, a majority (over 50%) of the older, subjectively
healthy Swiss population presented with 25(OH)D insuf-
ficiency/deficiency. We observed a progressive decline in
25(OH)D levels with aging both in women and men,
most likely due to lower sunlight exposure and a decline
in balanced food composition for those not (yet) part of
homes for retired, older persons, as those under study
10 - 20 21 - 29 ≥ 30
25(OH)D (ng/ml)
N = 403 N = 404 N = 381
< 10
1.4
1.2
1.0
0.8
0.0
N = 103
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Figure 3 25(OH)D levels and their relationship to C4 and C3. Comparison of concentrations of complement components C4 and C3 in 4
different 25(OH)D serum level groups and analysis of statistical significance. A and C: Set of data points with linear regression line. B and D:
Box-and-Whisker plot illustrating trend and statistical significance with variability outside the upper and lower quartiles.
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from North America, 31% of men aged 80 to 84 years had
levels <20 mg/ml [33], and the proportion increased to
40% in those >85 years [33]. It can be assumed that
Vitamin D insufficiency causes a substantial burden of dis-
ease (for example, falls, osteoporosis, arterial stiffness [34],
cardiovascular diseases [21], autoimmune disease, infectious
disease and neoplasia that would classify insufficiency as a
risk factor in our subjects rather than a past event.
In conjunction with these new insights, 25(OH)D testing
requests received by medical analytical laboratories are
surging worldwide [35]. The present study was performed
in compliance with current good laboratory practice, GLP.
The cutoffs for normal, insufficient or (severely) deficient
levels of vitamin D are defined at different levels based on
an original proposal [36]. Currently, the deficiency decisionlimit of vitamin D levels is set by an international agree-
ment at <20 ng/ml, although this cutoff is not recognized
by all [18,24]. Here we considered values <10 ng/ml as indi-
cative of severe deficiency. Since the separation into four
different effectual groups cannot relate to clinical features
in the healthy older persons studied, the cutoffs for 25(OH)
D levels do not target risk viz. no risk considerations [37].
Depending on latitude and climate, seasonal/monthly
variations in serum levels of 25(OH) do occur [33] or re-
main similar [38] and, in the cohort under study here, did
vary, reflected by incremental levels towards the end of
summer/fall. To the best of our knowledge, it is the first
time that we here report a seasonal variation of humoral
immunity components more or less consistently with 25
(OH)D levels. 25(OH)D insufficiency might also occur in
a sunny environment [38]. The variations in the levels of
Sakem et al. BMC Medicine 2013, 11:176 Page 7 of 9
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in our study might depend on changes in the microbio-
logical mosaic affecting us with Gram positive bacteria [39]
or else influenza H1N1 [40], examples of the most recently
studied pathogens eliciting differential humoral immune
responses. In the light of the interdependency of 25/OH)D/
humoral immunity found here, Vitamin D supplementa-
tion, therefore, must be considered the whole year round
on an individual risk/efficiency basis. A recent update of
circannual fluctuation of 25(OH)D in 50 kidney transplant
recipients found that (i) summer/winter peak-to-peak varia-
tions occur in our latitudes with an ensuing (ii) increased
frequency of 25(OH)D insufficiency during winter time
[41]; this finding contrasts somewhat with recent reports
from Israel [38] and South Africa [42].
To establish reference intervals (RIs), different statistical
procedures are commonly applied at each step. The sample
size in the >80-year group of the present study exceeds the
100-observation barrier. Indeed, the significant P-values
under non-parametric conditions highlight the findings that
incremental insufficiency progresses to deficiency with in-
creasing age, a finding not taken into account by the Endo-
crine Society’s Clinical Guidelines [24].
The ability of vitamin D to influence normal human
immunity is highly dependent on the 25(OH)D status of
individuals, and may lead to an aberrant response to infec-
tion or autoimmunity in those with insufficient vitamin D.
This article describes some of the recent developments
with respect to vitamin D and the immune system, and
possible clinical implications. The influence that 1,25(OH)
vitamin D exerts on the immune system sparks interest
for its potential for reducing infections and preventing
allograft rejection after transplantation [43].
Beyond the risk for rickets and osteoporosis, other dis-
eases are increasingly being noticed for their association
with Vitamin D status [44]. Therefore, we were interested
in the recently suggested role of vitamin D and its active
metabolite 1,25(OH)2D3 in modulating immune responses
[11,45,46]. Specific cell types involved in the immune
response express the enzyme CYP27B1, which produces
1,25(OH)2D3 in situ [47]. Recent studies suggest a role of
vitamin D in the reduction in the proliferation of immune
cells, their maturation to plasma cells and their production
of immunoglobulin [6]. Furthermore, 25(OH)D and human
IgG levels have been directly linked in recent reports
[15]. A potential explanation for the significant relation-
ship among IgA, IgG2 and vitamin D discovered in the
present study could be explained by the recently suggested
interplay between innate and adaptive immunity and the
role of T-cell cytokines and cytokine signaling [48,49],
which also might explain the dependency of 25(OH)D
levels and C4 and C3. In fact, interferon-γ potentiation of
Toll-like receptor-induced antimicrobial peptides is associ-
ated with CYP27B1 activity that leads to enhancedbioconversion of 25D3 to 1,25D3 in the vitamin D-
dependent antimicrobial pathway [50].
In vitro, the effects of 1,25(OH)2D3 on lymphocyte prolif-
eration and cytokine production by PBMCs are pleiotropic
[51]. Total serum IgG levels were previously reported to
have a negative association with serum 25(OH)D [15],
although such association was not present in cerebrospinal
fluid [52] nor in our study. Low levels of 25(OH)D are thus
a finding occurring in healthy older persons and might have
an impact on immune defense.
Conclusions
The majority (approximately two-thirds) of healthy older
Swiss subjects present with vitamin D insufficiency.
Showing the impact on serum concentrations of IgG1,
IgG2, IgA and complement components C4 and C3,
more so in severe cases of vitamin D deficiency, but
also with insufficiency of 25(OH)D, this study supports a
role of vitamin D in the immune system under immuno-
competent conditions.
Additional files
Additional file 1: Monthly variation of 25(OH)D and components of
the humoral immune system in older Swiss. Monthly follow-up of
mean ± 1 SD serum levels of 25(OH)D and humoral immune
components. The IgE increment in summer likely reflects pollen exposure
of the subjects. Number of samples collected per month are listed in
brackets on the abscissa.
Additional file 2: Percentage increase/decrease in level of 25(OH)D
and humoral immune components in older Swiss. The percentage
increase or decrease in seasonal variation of the humoral immune
components showing significant correlation in seasonal variation with
25(OH)D, compared to the month of January (100%) is further
illustrated here.
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